ArticleCancers2021
Preclinical Safety Evaluation of Intranasally Delivered Human Mesenchymal Stem Cells in Juvenile Mice.
Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 23 citations in OpenAlex.
- miR-26b-modified human umbilical cord mesenchymal stem cells exhibit enhanced anti-fibrotic efficacy in a mouse model of hepatic fibrosis.Molecular biology reports · 2026Article
- Microglia Rank signaling regulates GnRH neuronal function and the hypothalamic-pituitary-gonadal axis.Science (New York, N.Y.) · 2026Article
- Review
- Impaired therapeutic efficacy of sleep-deprived bone marrow mesenchymal stem cells in the cerebellum of mouse cuprizone model of multiple sclerosis: stereological and motor behavioral evidence.Journal of molecular histology · 2025Article
- Craniomaxillofacial-Derived MSCs in Congenital Defect Reconstruction.Biomolecules · 2025Review
- Glioblastoma progression is hindered by melatonin-primed mesenchymal stromal cells through dynamic intracellular and extracellular reorganizations.Theranostics · 2025Article
- 3D bioprinting of prefabricated artificial skin with multicomponent hydrogel for skin and hair follicle regeneration.Theranostics · 2025Article
- Umbilical cord mesenchymal stromal cells in serum-free defined medium display an improved safety profile.Stem cell research & therapy · 2023Article
- Stability and biosafety of human epidermal stem cell for wound repair: preclinical evaluation.Stem cell research & therapy · 2023Article
- Generation of mesenchymal stromal cells from urine-derived iPSCs of pediatric brain tumor patients.Frontiers in immunology · 2023Article
- Brain Organoids to Evaluate Cellular Therapies.Animals : an open access journal from MDPI · 2022Article
- Glial Response to Intranasal Mesenchymal Stem Cells in Intermittent Cuprizone Model of Demyelination.Neurotoxicity research · 2022Article
- Nose-to-Brain: The Next Step for Stem Cell and Biomaterial Therapy in Neurological Disorders.Cells · 2022Review
- Heterogeneity of In Vitro Expanded Mesenchymal Stromal Cells and Strategies to Improve Their Therapeutic Actions.Pharmaceutics · 2022Review
- State of the field: cellular and exosomal therapeutic approaches in vascular regeneration.American journal of physiology. Heart and circulatory physiology · 2022Review
- Editorial: Mesenchymal Stromal Cell Therapy for Regenerative Medicine.Frontiers in cellular neuroscience · 2022Article
- Current State and Future Directions of Intranasal Delivery Route for Central Nervous System Disorders: A Scientometric and Visualization Analysis.Frontiers in pharmacology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
Abstract
Mesenchymal stem cell (MSC)-based therapy is a promising therapeutic approach in the management of several pathologies, including central nervous system diseases. Previously, we demonstrated the therapeutic potential of human adipose-derived MSCs for neurological sequelae of oncological radiotherapy using the intranasal route as a non-invasive delivery method. However, a comprehensive investigation of the safety of intranasal MSC treatment should be performed before clinical applications. Here, we cultured human MSCs in compliance with quality control standards and administrated repeated doses of cells into the nostrils of juvenile immunodeficient mice, mimicking the design of a subsequent clinical trial. Short- and long-term effects of cell administration were evaluated by in vivo and ex vivo studies. No serious adverse events were reported on mouse welfare, behavioral performances, and blood plasma analysis. Magnetic resonance study and histological analysis did not reveal tumor formation or other abnormalities in the examined organs of mice receiving MSCs. Biodistribution study reveals a progressive disappearance of transplanted cells that was further supported by an absent expression of human GAPDH gene in the major organs of transplanted mice. Our data indicate that the intranasal application of MSCs is a safe, simple and non-invasive strategy and encourage its use in future clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.